Chen Haiyang, Tao Meng, Li Ding, Han Jing, Cheng Cheng, Ma Yanfang, Wu Yingxi, Shelat Vishal G, Tustumi Francisco, Satapathy Sanjaya K, Kang Koo Jeong, Wang Qiming
Department of Internal Medicine, Henan Cancer Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
Department of General Surgery, Huaihe Hospital of Henan University, Kaifeng, China.
Ann Transl Med. 2021 Jun;9(12):1004. doi: 10.21037/atm-21-2611.
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide. Clinical practice guidelines (CPGs) on the prevention, surveillance, diagnosis and management of HCC are essential to guide clinical practice. The objective of this study was to evaluate the reporting quality of the most recent CPGs for HCC published worldwide.
We systematically searched literature databases and websites of guideline development organizations and medical associations to extract CPGs on HCC published between January 2018 and December 2020. We evaluated the reporting quality using the Reporting Items for practice Guidelines in Healthcare (RIGHT) statement. We assessed for each of the 35 RIGHT checklist items whether the guidelines reported the corresponding information. We calculated the mean (± standard error of the mean, SEM) percentages of the guidelines' compliance with the items (reporting rate), both overall and for each of the seven domains of the RIGHT checklist.
We identified 22 guidelines, of which three (14%) were written in Chinese and 19 (86%) in English. The mean ±SEM overall reporting rate in the twenty-two guidelines was 56%±4%. The reporting rates of the seven domains were the following: basic information 81%±3%, background 58%±6%, evidence 58%±6%, recommendations 59%±5%, review and quality assurance 34%±10%, funding and declaration and management of interests 39%±4%, and other information 23%±6%.
The reporting quality of the recently published guidelines for HCC was suboptimal. While there is no doubt about the great value of the CPGs' recommendations in clinical practice, the reporting in CPGs for HCC still needs improvement.
肝细胞癌(HCC)是全球最常见的恶性肿瘤之一。关于HCC预防、监测、诊断和管理的临床实践指南(CPG)对于指导临床实践至关重要。本研究的目的是评估全球发布的最新HCC CPG的报告质量。
我们系统检索了文献数据库以及指南制定组织和医学协会的网站,以提取2018年1月至2020年12月期间发布的关于HCC的CPG。我们使用医疗保健实践指南报告条目(RIGHT)声明来评估报告质量。我们针对RIGHT清单的35个条目中的每一项,评估指南是否报告了相应信息。我们计算了指南对这些条目的总体及RIGHT清单七个领域中每个领域的平均(±平均标准误差,SEM)合规百分比(报告率)。
我们识别出22份指南,其中3份(14%)为中文撰写,19份(86%)为英文撰写。22份指南的总体平均报告率为56%±4%。七个领域的报告率如下:基本信息81%±3%,背景58%±6%,证据58%±6%,推荐意见59%±5%,审查与质量保证34%±10%,资金及利益声明与管理39%±4%,以及其他信息23%±6%。
最近发布的HCC指南的报告质量欠佳。虽然CPG的推荐意见在临床实践中的巨大价值毋庸置疑,但HCC CPG的报告仍需改进。